PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced ...
Cancer
May 15, 2013 |
not rated yet |
0
Pharmaceutical advances offer new options for health outcomes
Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.
Diseases, Conditions, Syndromes
22 hours ago |
not rated yet |
0
